DCGO Stock - DocGo Inc.
Unlock GoAI Insights for DCGO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $616.56M | $624.29M | $440.52M | $318.72M | $94.09M |
| Gross Profit | $213.57M | $195.38M | $154.72M | $109.75M | $31.35M |
| Gross Margin | 34.6% | 31.3% | 35.1% | 34.4% | 33.3% |
| Operating Income | $28.69M | $15.05M | $21.83M | $15.36M | $-14,757,683 |
| Net Income | $19.99M | $6.86M | $34.58M | $23.74M | $-14,359,944 |
| Net Margin | 3.2% | 1.1% | 7.9% | 7.4% | -15.3% |
| EPS | $0.20 | $0.07 | $0.34 | $0.30 | $-0.14 |
DocGo, Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home and offices; COVID-19 testing; and event services, which include on-site healthcare support at sporting events and concerts. DocGo, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 9th 2025 | BTIG Research | Downgrade | Neutral | - |
| February 28th 2025 | Deutsche Bank | Downgrade | Hold | $2.85← $5 |
| August 18th 2023 | BTIG Research | Initiation | Buy | $15 |
| April 21st 2023 | Cantor Fitzgerald | Initiation | Overweight | $11 |
| April 19th 2022 | Deutsche Bank | Initiation | Buy | $11 |
Earnings History & Surprises
DCGOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.10 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.09 | $-0.11 | -22.2% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.06 | $-0.11 | -83.3% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.01 | $-0.09 | -800.0% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $0.05 | $0.04 | -20.0% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $0.05 | $0.05 | 0.0% | = MET |
Q3 2024 | Aug 7, 2024 | $0.08 | $0.07 | -12.5% | ✗ MISS |
Q2 2024 | May 8, 2024 | $0.08 | $0.10 | +25.0% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $0.10 | $0.07 | -30.0% | ✗ MISS |
Q4 2023 | Nov 6, 2023 | $0.06 | $0.05 | -16.7% | ✗ MISS |
Q3 2023 | Aug 7, 2023 | $-0.01 | $-0.02 | -166.7% | ✗ MISS |
Q2 2023 | May 8, 2023 | $-0.01 | $-0.03 | -238.6% | ✗ MISS |
Q1 2023 | Mar 13, 2023 | $0.05 | $0.11 | +120.0% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $0.05 | $0.05 | 0.0% | = MET |
Q3 2022 | Aug 8, 2022 | $0.02 | $0.07 | +199.9% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $0.05 | $0.09 | +80.0% | ✓ BEAT |
Q1 2022 | Mar 14, 2022 | $0.01 | $0.17 | +1050.2% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | — | $0.04 | — | — |
Q3 2021 | Aug 11, 2021 | — | $-0.02 | — | — |
Latest News
CORRECTION: DocGo Q3 Adj. EPS $(0.11) Beats $(0.12) Estimate, Sales $70.810M Beat $69.770M Estimate
📈 PositiveDocGo shares are trading lower after the company reported mixed Q3 financial results and narrowed its FY25 sales guidance.
📉 NegativeDocGo Narrows FY2025 Sales Guidance from $300.000M-$330.000M to $315.000M-$320.000M vs $317.559M Est
➖ NeutralDocGo Q3 EPS $(0.28) Misses $(0.12) Estimate, Sales $70.810M Beat $69.770M Estimate
➖ NeutralDocGo Plans To Roll Out Longitudinal Care Services In Q4 In Collaboration With California-Based Insurance Provider
📈 PositiveDocGo shares are trading higher after the company acquired virtual care platform SteadyMD, which is expected to generate about $25 million in 2025 revenue and be EBITDA positive in 2026.
📈 PositiveDocGo stock surges on deal to acquire virtual care platform SteadyMD
📈 PositiveDocGo Acquires Virtual Care Platform SteadyMD; No Financial Terms Disclosed; In 2025, SteadyMD Is Expected To Generate ~$25M In Revenue And Is Expected To Be EBITDA Positive For 2026
📈 PositiveCanaccord Genuity Maintains Hold on DocGo, Raises Price Target to $1.6
➖ NeutralFrequently Asked Questions about DCGO
What is DCGO's current stock price?
What is the analyst price target for DCGO?
What sector is DocGo Inc. in?
What is DCGO's market cap?
Does DCGO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to DCGO for comparison